drugset / Trial / NCT03418818

FAZA PET/MRI Sarcoma

NCT03418818

Active not recruiting 70 enrolled University Health Network, Toronto
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This is a dual arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans. FAZA PET/MRI will be used to measure hypoxia in sarcoma tissues and will occur for: Arm A: before neo-adjuvant radiation/chemotherapy treatment; Arm B: before surgery (optional). After the FAZA PET/MRI scan, patients will be followed up via telephone, 48 hours after the scan, to see if there are any side effects due to FAZA. Up to 50 patients enrolled in Arm B will receive pimonidazole approximately 16-20 hours before surgery.

Timeline

Start
2018-03-27
Primary completion
2028-10
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FAZA Diagnostic / imaging agent
Subject Pimonidazole Diagnostic / imaging agent

Indications